Astellas Pharma, Inc. is to acquire the private US company Propella Therapeutics, Inc. in a $175m deal that will bring with it an early clinical-stage asset for prostate cancer, a core area of interest to the Japanese firm and where it is facing a major patent expiry in the next few years.
Propella Acquisition To Shore Up Astellas’s Prostate Cancer Presence
Advantages Seen Over Zytiga
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
More from Strategy
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.